This story has been corrected to reflect that OVA1 is a risk assessment test, not a rule-out test. Also, Vermillion shifted to a focus on OVA1's negative predictive value in 2016, and the list price of CA125 is around $200. We apologize for the errors.

NEW YORK (360Dx) –Vermillion is eyeing 2019 as a breakout year for its OVA1 ovarian cancer test, as the company continues piecing together the pricing, payor, and publication elements it hopes will lay the ground work for a successful renewed sales push.